Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Diabet Med ; 28(8): 896-9, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21749442

ABSTRACT

AIMS: Type 1 diabetes and autoimmune thyroiditis are common autoimmune diseases characterized by the presence of autoantibodies against tissue-specific components. Non-thyroid-specific autoantibodies are frequent in patients with autoimmune thyroiditis. The prevalence of Type 1 diabetes autoantibodies in patients with autoimmune thyroiditis is unknown. METHODS: The prevalence of Type 1 diabetes autoantibodies (GAD and IA2) was analysed in 236 Sardinian children and adolescents with autoimmune thyroiditis. GAD and IA2 antibodies were measured at the time of the diagnosis of autoimmune thyroiditis and re-evaluated after 1 year in the children who were shown to be positive. Autoantibody prevalence was evaluated in 949 healthy age-matched controls. RESULTS: The prevalence of GAD and/or IA2 antibodies was 8% in the children and adolescents with autoimmune thyroiditis and 4.1% in control subjects (P = 0.017). When Type 1 diabetes autoantibodies were separately analysed, the difference remained significant for IA2 (3.39% in autoimmune thyroiditis vs. 1.16% in control subjects, P = 0.012), but not for GAD (5.1% in autoimmune thyroiditis vs. 3.79% in control subjects, P = 0.367). Seven of 10 children with autoimmune thyroiditis and detectable Type 1 diabetes autoantibodies at the diagnosis remained positive after 1 year. In the course of 2 years of follow-up, two patients who were positive for Type 1 diabetes autoantibodies at the time of diagnosis of autoimmune thyroiditis developed diabetes. CONCLUSIONS: This is the first study reporting the prevalence of Type 1 diabetes autoantibodies in a selected cohort of genetically homogeneous children and adolescents with autoimmune thyroiditis. The main finding was that the prevalence of Type 1 diabetes autoantibodies and of newly diagnosed Type 1 diabetes in patients with autoimmune thyroiditis was significantly higher than that observed in the general paediatric population, suggesting that children with autoimmune thyroiditis are at increased risk of developing Type 1 diabetes.


Subject(s)
Autoantibodies/immunology , Diabetes Mellitus, Type 1/immunology , Glutamate Decarboxylase/immunology , Protein Tyrosine Phosphatases/immunology , Thyroiditis, Autoimmune/immunology , Adolescent , Autoantibodies/classification , Child , Diabetes Mellitus, Type 1/epidemiology , Female , Glutamate Decarboxylase/classification , Humans , Italy/epidemiology , Male , Protein Tyrosine Phosphatases/classification
2.
Thyroid ; 11(9): 849-57, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11575854

ABSTRACT

The relationship among iodine intake, goiter prevalence, and thyroid autoimmunity remains controversial. In the present article, we report the prevalence of antithyroid antibodies (ATA) in relation to iodine intake, frequency of goiter, and thyroid function in a large group of Sardinian schoolchildren living in areas with borderline iodine sufficiency, or mild to moderate iodine deficiency. A total of 8,040 schoolchildren (4,194 males, 3,846 females, ages 6-15 years) from 29 communities were examined between 1986-1994. Thyroid size was assessed by palpation, according to the Pan American Health Organization (PAHO) criteria. In all cases antimicrosomal (MAb) or antithyroid peroxidase antibodies (TPOAb) and thyrotropin (TSH) were assayed. Urinary iodine was determined in a subgroup of 820 children. ATA was detected in 235 (2.92%) sera (88 males, 2.12%; 147 females, 3.82%; chi2 = 20.41, p < 0.0001). ATA prevalence ranged between 0.0%-7.3% in the 29 communities without any geographical correlation with goiter prevalence and urinary iodine excretion. However, ATA was more frequently detected in goitrous children, especially in females. The presence of ATA was not age-dependent in males, whereas a significant increase of ATA was observed in females older than 11 years of age. Seventy-seven (0.96%) children showed borderline to slightly increased serum TSH (>5.2-32 mU/L). Increased serum TSH concentration was more frequently found in children with ATA, especially at higher titers. In summary, our study in Sardinian schoolchildren indicates: (1) ATA display geographical heterogeneity, which seems to be unrelated to goiter prevalence and/or to iodine supply; (2) ATA are more frequently detected in females older than 11 years of age, suggesting that puberty has a role in determining the predominance in females of thyroid autoimmunity; (3) although most goitrous children are ATA-negative, the prevalence of ATA is increased in children with enlarged glands; (4) ATA is associated with an increased prevalence of subclinical hypothyroidism.


Subject(s)
Autoantibodies/blood , Autoimmunity , Goiter/epidemiology , Thyroid Gland/physiology , Adolescent , Age Distribution , Child , Female , Goiter/immunology , Humans , Hypothyroidism/epidemiology , Hypothyroidism/immunology , Italy , Male , Prevalence , Sex Distribution , Thyroid Diseases/immunology , Thyroid Gland/immunology
3.
J Clin Psychopharmacol ; 21(6): 594-8, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11763007

ABSTRACT

The objective of this paper was to study prospectively the course of clinically relevant thyroid dysfunction in a cohort of patients on long-term lithium treatment. Patients (N = 150) who had undergone a cross-sectional evaluation of their thyroid function in 1989, when they were at different stages of lithium treatment, were followed up for the presence of thyroid autoimmunity, hypothyroidism, and goiter during a further period of lithium exposure of up to ten years. The following annual rates of newly developed thyroid dysfunction were observed: autoimmunnity (1.4%), subclinical hypothyroidism (1.7%), and goiter (2.1%). Subjects with thyroid autoimmunity had a higher chance of requiring substitution treatment with levothyroxine for subclinical hypothyroidism compared with subjects with no evidence of thyroid autoimmunity (13/32 = 41% versus 7/118 = 6%). Subjects (N = 15) who were prescribed carbamazepine in addition to lithium showed a significant decrease of TSH concentrations. In patients already being treated with lithium for several years, the overall incidence of hypothyroidism, goiter, and thyroid autoimmunity were comparable with those reported for the general population. However, lithium exposure may represent an additional risk factor for hypothyroidism in women and/or in the presence of thyroid autoimmunity.


Subject(s)
Antimanic Agents/therapeutic use , Lithium Chloride/therapeutic use , Thyroid Function Tests/statistics & numerical data , Antimanic Agents/adverse effects , Autoantibodies/blood , Carbamazepine/adverse effects , Carbamazepine/therapeutic use , Confidence Intervals , Drug Therapy, Combination , Female , Follow-Up Studies , Goiter/blood , Goiter/chemically induced , Goiter/epidemiology , Humans , Hypothyroidism/blood , Hypothyroidism/chemically induced , Hypothyroidism/epidemiology , Lithium Chloride/adverse effects , Male , Prospective Studies , Thyroglobulin/immunology
4.
Am J Gastroenterol ; 93(6): 976-9, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9647032

ABSTRACT

OBJECTIVE: We sought to reevaluate the prevalence of thyroid dysfunction and thyroid autoimmunity in 47 patients with celiac disease; 91 healthy subjects were studied as controls. Both patients and controls were from Sardinia, Italy. METHODS: Diagnosis of celiac disease was made on the basis of clinical history, presence of positive antigliadin IgA (AGA-A) and IgG (AGA-G) antibodies, antireticulin antibodies (ARA), antiendomysium antibodies (EMA), and was confirmed by jejunal biopsy. HLA class II typing for DQB1 and DQA1 alleles was performed in 36/47 celiac patients. Thyroid was evaluated by palpation and echography; serum free thyroid hormones (FT4, FT3), thyrotropic hormone (TSH), and antithyroid peroxidase autoantibodies (anti-TPO) were assayed by radioimmunoassays. RESULTS: The prevalence of anti-TPO was higher in celiac patients (29.7%) than in healthy controls (9.6%) (p < 0.001) and thyroid echography frequently displayed (42.5%) a hypoechogenic pattern. Five anti-TPO-positive celiac patients were hypothyroid (two overt, three subclinical). A higher but not significantly different prevalence of anti-TPO (3/7 = 42.8%) was found in celiac patients displaying the DQB1*0502 genotype, when compared with the remaining patients (8/29 = 27.6%). CONCLUSIONS: An elevated prevalence of clinical and subclinical autoimmune thyroid autoimmunity was found in Sardinian celiac patients, especially in those displaying the DQB1*0502 genotype; this finding could be related to a particular genetic background of the Sardinian population.


Subject(s)
Celiac Disease/complications , Thyroid Diseases/complications , Adult , Aged , Aged, 80 and over , Autoantibodies/analysis , Celiac Disease/genetics , Celiac Disease/immunology , Female , Genotype , Gliadin/immunology , HLA-DQ Antigens/analysis , HLA-DQ alpha-Chains , HLA-DQ beta-Chains , Humans , Immunoglobulin A/analysis , Immunoglobulin G/analysis , Iodide Peroxidase/immunology , Italy , Male , Middle Aged , Reticulin/immunology , Thyroid Diseases/diagnostic imaging , Thyroid Diseases/immunology , Thyroid Hormones/blood , Thyrotropin/blood , Ultrasonography
5.
Neuropsychobiology ; 36(1): 37-41, 1997.
Article in English | MEDLINE | ID: mdl-9211443

ABSTRACT

Psychiatric patients on long-term lithium (Li) therapy frequently develop goiter and/or hypothyroidism. It has also been suggested that Li may trigger/exacerbate thyroid autoimmunity. Previous studies provided evidence that underlying thyroid diseases represent important predisposing factors for the development of Li-induced thyroid dysfunction. The aim of the present paper was to assess the value of thyroid ultrasound-a simple and reliable tool to detect subtle thyroid abnormalities-in the longitudinal evaluation of 23 Li-treated psychiatric patients without evidence of biochemical thyroid abnormalities before therapy. For this purpose, thyroid ultrasound was associated with a clinical and laboratory (serum thyroxine, serum triiodothyronine, serum TSH, antithyroglobulin (AbTg), antithyroid microsomal (AbM) and antithyroid peroxidase autoantibodies) evaluation prior to and at 6- to 12-month intervals during Li treatment. On the basis of thyroid ultrasound before Li, patients were subdivided into two groups: group A (n = 15, 7 males, 8 females) with a normal echography and group B (n = 8, 5 males, 3 females) with mild ultrasound abnormalities. In group A the development of a small diffuse goiter was confirmed by physical examination during Li therapy; 2 patients displayed a transient increase of serum TSH concentration and none developed detectable serum antithyroid autoantibodies. Beside the small volumetric increase, no other ultrasound abnormalities were observed during the entire follow-up. In all group B patients a mild diffuse goiter was clinically detected before and on Li administration and no significant volumetric changes were observed during follow-up. Two patients developed high titers of AbM and AbTg 12 and 18 months after the beginning of Li, respectively; in 1 a persistent increase of serum TSH concentration was also observed. Thyroid echography before Li displayed different degrees of scattered or diffuse hypoechogenicity and a further decrease in echogenicity was detected during Li therapy in 2 patients. In conclusion, we provided further evidence that long-term Li administration is not associated with de novo appearance of thyroid autoimmune phenomena in humans, but rather with an exacerbation of underlying thyroid autoimmunity. In addition to thyroid autoantibody and TSH measurements, thyroid echography appears to be a sensitive tool in the identification of patients at risk of developing autoimmune hypothyroidism during long-term Li therapy.


Subject(s)
Bipolar Disorder/drug therapy , Echocardiography , Goiter/chemically induced , Hypothyroidism/chemically induced , Lithium Carbonate/adverse effects , Psychotic Disorders/drug therapy , Adult , Autoantibodies/blood , Bipolar Disorder/diagnostic imaging , Bipolar Disorder/psychology , Drug Monitoring , Female , Follow-Up Studies , Goiter/diagnostic imaging , Humans , Hypothyroidism/diagnostic imaging , Lithium Carbonate/therapeutic use , Longitudinal Studies , Male , Middle Aged , Psychotic Disorders/diagnostic imaging , Psychotic Disorders/psychology , Thyroid Gland/diagnostic imaging , Thyroid Gland/drug effects , Thyroid Gland/immunology , Thyroid Hormones/blood , Thyroiditis, Autoimmune/chemically induced , Thyroiditis, Autoimmune/diagnostic imaging
6.
Acta Psychiatr Scand ; 94(1): 45-8, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8841676

ABSTRACT

A cohort of patients at various stages of lithium treatment was followed up for 6 years in order to evaluate the course of thyroid abnormalities. Ultrasonography confirmed that lithium can increase thyroid size, especially in cigarette smokers, and that it can affect the texture of the gland. However, the incidence of clinical hypothyroidism or specific thyroid autoimmunity does not exceed that found in the general population. Repeated determinations of thyrotrophin (TSH) concentrations can prevent clinically relevant consequences. Addition of carbamazepine to lithium can counteract lithium-induced subclinical hypothyroidism, possibly improving prophylactic efficacy in recurrent affective disorders.


Subject(s)
Antipsychotic Agents/therapeutic use , Lithium/therapeutic use , Thyroid Gland/drug effects , Antibodies , Anticonvulsants/pharmacology , Anticonvulsants/therapeutic use , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Carbamazepine/pharmacology , Carbamazepine/therapeutic use , Drug Therapy, Combination , Female , Follow-Up Studies , Goiter/etiology , Humans , Hypothyroidism/etiology , Lithium/adverse effects , Lithium/metabolism , Male , Mood Disorders/drug therapy , Retrospective Studies , Thyroid Gland/diagnostic imaging , Thyrotropin/immunology , Ultrasonography
8.
Horm Metab Res ; 26(11): 548-51, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7875652

ABSTRACT

In hypothyroid patients serum soluble IL-2 receptor levels showed scattered and conflicting results. In our report we studied circulating soluble interleukin 2 receptors in 22 patients with hypothyroid autoimmune thyroiditis before L-thyroxine treatment and when the patients became euthyroid. The mean of soluble Interleukin 2 receptor levels in the hypothyroid state was 48.6 pmol/l (95% confidence interval, 45.6-51.5) statistically lower than in the controls (95% confidence interval, 86.4 pmol/l, 83.3-89.4) (p < 0.0001). When the patients became euthyroid during L-thyroxine treatment, soluble Interleukin 2 receptor levels increased, showing mean values comparable to the controls. A positive high correlation (p < 0.001) was observed between soluble Interleukin 2 receptor levels and thyroxine free levels in the hypothyroid as well as in the euthyroid state and between soluble Interleukin 2 receptors and the mean weekly L-thyroxine dose. Our study confirmed that in the hypothyroid state, the behaviour of soluble Interleukin 2 receptors is anomalous as compared to other autoimmune diseases. In fact a strict relationship exists between the levels of thyroid hormones and soluble Interleukin 2 receptors but not between the latter and antithyroid antibodies. These results agree with those supporting a role for thyroid hormones in the regulation of the immune system. They also suggest that the measurement of soluble Interleukin 2 receptors could be used as a marker of the peripheral action of thyroid hormones.


Subject(s)
Hypothyroidism/blood , Receptors, Interleukin-2/metabolism , Thyroiditis, Autoimmune/blood , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...